Viracta Therapeutics, Inc. (VIRX) [Rocket]

Overview

Viracta Therapeutics, Inc. (VIRX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/04/2023	8-K	Other Events, Financial Statements and Exhibits  Interactive Data
08/18/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023	3	Cohen Darrel P. (Chief Medical Officer) has filed a Form 3 on Viracta Therapeutics, Inc.
08/14/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/14/2023	8-K	Quarterly results
08/07/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-05-20	Dec-31-19	Dec-31-18
Revenues	0.0	26.3	13.5	23.9	0.1	13.5	2.1	0.2
Revenue growth	-100.0%	10.1%	11150.0%	77.2%	-94.2%		774.7%	-64.6%
Cost of goods sold	0.0	50.6	0.0	127.8	0.0	18.8	0.0	0.0
Gross profit	0.0	-24.3	13.5	-103.9	0.1	-5.3	2.1	0.2
Gross margin		-92.6%	100.0%	-435.5%	100.0%	-39.7%	100.0%	100.0%
Selling, general and administrative
Research and development	26.3		23.9		12.3		15.4	14.6
General and administrative	24.3	24.3	15.4	15.4	10.2	5.3	9.9	11.3
EBIT	-50.6	-50.6	-25.8	-114.3	-22.3	-18.8	-23.3	-25.7
EBIT margin		-192.6%	-191.1%	-478.9%	-18585.8%	-139.7%	-1123.4%	-10848.1%
Pre-tax income	-49.2	-49.2	-114.8	-114.8	-21.6	0.0	-23.3	-26.6
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%	0.0%
Net income	-49.2	-49.2	-114.8	-114.8	-21.6	0.0	-23.3	-26.6
Net margin		-187.3%	-850.1%	-481.0%	-18008.3%	0.0%	-1125.4%	-11230.0%

Diluted EPS	($1.30)	($1.30)	($3.60)	($3.60)	($1.53)	$0.00	($2.68)	($0.75)
Shares outstanding (diluted)	37.8	37.8	31.9	31.9	14.1	324.7	8.7	35.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.